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Abstract
We have previously reported that immunization of the severe combined immunodeﬁciency (SCID) mice reconstituted with
human peripheral blood mononuclear cells (PBMC) (hu-PBL-SCID mice) with inactivated human immunodeﬁciency virus
type-1 (HIV-1)-pulsed-autologous dendritic cells (HIV-DC) elicits HIV-1-reactive CD4
þ T cells that produce an as yet to be
deﬁned novel soluble factor in vitro with anti-viral properties against CCR5 tropic (R5) HIV-1 infection. These ﬁndings led
us to perform studies designed to identify the lineage of the cell that synthesizes such a factor in vivo and deﬁne the epitopes
of HIV-1 protein that have speciﬁcity for the induction of such anti-viral factor. Results of our studies show that this property
is a function of CD4
þ but not CD8
þ T cells. Human CD4
þ T cells were thus recovered from the HIV-DC-immunized hu-
PBL-SCID mice and were re-stimulated in vitro by co-culture for 2 days with autologous adherent PBMC as antigen
presenting cells, APC previously pulsed with inactivated HIV in IL-2-containing medium to expand HIV-1-reactive CD4
þ T
cells. Aliquots of these re-stimulated CD4
þ T cells were then co-cultured with similar APC’s that were previously pulsed with
10mg/ml of a panel of HIV peptides for an additional 2 days, and their culture supernatants were examined for the
production of both the R5 HIV-1 suppression factor and IFN-g. The data presented herein show that the HIV-1 primed
CD4
þ T cells produced the R5 suppression factor in response to a wide variety of HIV-1 gag, env, pol, nef or vif peptides,
depending on the donor of the CD4
þ T cells. Simultaneous production of human interferon (IFN)-g was observed in some
cases. These results indicate that human CD4
þ T cells in PBMC of HIV-1 naive donors have a wide variety of HIV-1
epitope-speciﬁc CD4
þ T cell precursors that are capable of producing the R5 HIV-1 suppression factor upon DC-based
vaccination with whole inactivated HIV-1.
Keywords: HIV-1, vaccination, dendritic cells, HIV-1 suppression
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Th, helper T; hu-PBL-SCID mouse, severe combined immunodeﬁciency mouse engrafted with human PBMC; AT-2,
aldrithiol-2; 50% TCID50, tissue culture infectious dose
Introduction
Virus speciﬁc CD4
þ helper T (Th) cell responses have
been shown to play an essential role in the
maintenance of effective immune responses in a
variety of animal models [3,12,20,32,34]. Human
immunodeﬁciency virus type 1 (HIV-1) infection is
associated with a progressive loss of total CD4
þ Th
cells by both direct and indirect mechanisms
[21,25,27,28,30]. In particular, memory CD4
þ Th
cells become more susceptible to the cytopathic effects
of HIV-1 than naive CD4
þ Th cells after activation
[8]. Several lines of evidence strongly suggest that
HIV-1-speciﬁc CD4
þ Th cells are critical for control
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CD8
þ cytotoxic T lymphocyte (CTL) responses
[13,17,22,23,26,28]. Highlighting the complexity of
HIV-1 infection was the ﬁnding that HIV-1-speciﬁc
CD4
þ Th cells were in fact preferentially infected
by HIV-1 in vivo [9]. It was reasoned that such
mechanisms may indeed contribute to an impairment
in the control of not only HIV-1 but also opportunistic
infections. While such CD4
þT cell depletion con-
tinues to occur with variable kinetics in HIV-1 infected
patients, a signiﬁcant frequency of HIV-1-speciﬁc
CD4
þ Th cells are detectable in most of these
individuals with a higher frequency in long-term non-
progressors (LTNP) than in subjects during progress-
ive disease [4,28,37,38]. In addition to the traditional
function of CD4
þ T cells in facilitating the generation
of HIV-1 speciﬁc CD8
þ T cells and the synthesis of
antibodies, CD4
þ Th cells from HIV-1 infected
patients havealso been shownto exert anti-viral effects
not only by direct lysis of HIV-1 infected target cells by
HIV-1 gag speciﬁc CD4
þ T cells [18] but also by the
secretion of a variety of HIV-1 suppression factors
[1,15,31,41]. These ﬁndings together suggest that
CD4
þ T cells from HIV-1 infected and/or immunized
individuals have acquired a series of unique anti-viral
activity which may contribute to the control of viremia
and the detailed studies of the mechanisms by which
such activity is acquired and induced thus appears
warranted. We have previously reported that SCID
mice engrafted with HIV-1-naive human PBMC
together with autologous DC pulsed with inactivated
whole HIV-1 virion became subsequently completely
resistant to R5 HIV-1 challenge in vivo. The resistance
to infection was speciﬁc since it was only seen in
the hu-PBL-SCID mice immunized with inactivated
R5orX4HIV-1virions, but notOVAorKLH.Studies
of the mechanisms by which these mice were
protected led to the discovery of a novel soluble
anti-viral factor produced in the serum of
these HIV-DC immune mice. While this factor
synthesized by human CD4
þ Tc e l l sf r o mt h e
hu-PBL-SCID HIV-1 immunized mice was unable
to neutralize HIV-1 in vitro, it was capable of inhibiting
R5, but not X4 HIV-1 infection of primary
macrophages and activated PBMC which was not
secondary to the down regulation of either CCR5 or
CD4 and appeared to act prior to viral integration. Of
interest was also the ﬁnding that the factor was not
effective in controlling R5 HIV-1 infection of CCR5-
expressing CD4
þT cell lines.
Since the generation of the suppressor factor
appeared to be speciﬁcally induced by HIV-1
immunization of the hu-PBL-SCID mice, it was
reasoned that the delineation of the epitopes of the
HIV-1 encoded proteins that induce the generation
of such factors would be appropriate and informa-
tive. Results of such studies are the basis of this
report.
Materials and methods
Mice
SCID mice lacking functional T, B and natural killer
cells (NK), BALB/c-rag2
2/2 gc
2/2 [24] were used in
the present study. The mice were kept in a SPF and
BSL-3 animal facilities of the Laboratory Animal
Center, University of the Ryukyus. The protocols for
the care and use of hu-PBL-SCID mice have been
approved by the committee on animal research of the
University of the Ryukyus.
Reagents
RPMI 1640 medium (SIGMA, St Louis, MO)
supplemented with 5% fetal calf serum (FCS),
100U/ml of penicillin and 100mg/ml of streptomycin
(hereinafter called RPMI medium), serum free
medium (AIM-V) and Iscove’s medium (Lifetechnol-
ogy, NY) supplemented with 10% FCS with the
antibiotics (hereinafter called AIM-V medium and
Iscove’s medium) were utilized as sources of media.
Soluble recombinant human IL-4 and GM-CSF were
produced in 293 T cells transfected with pCMhIL4
and pCMhGM (RIKEN Gene Bank, Ibaraki, Japan),
respectively, by the calcium phosphate method [33]
and puriﬁed. Concentrations of human IL-4 and GM-
CSF were determined using commercial ELISA kits
(BioSource, Camarillo, CA). Human recombinant
IL-2 was kindly supplied by NIH AIDS Research and
Reference Program.
Blocking monoclonal antibodies (mAb) against
human MIP-1a,h u m a nM I P - 1 b and human
RANTES were purchased from R&D systems
(Rockville, MD). To maintain their blocking activity,
these antibodies in a lyophilized form were recon-
stituted in accordance with the manufacturer’s
instructions, and aliquots were kept at 2808C until
use. Heparin–Sepharose (Pharmacia, Sweden) was
used to absorb b-chemokines as described previously
in Ref. [39].
HIV-1 peptides were obtained from the NIH AIDS
Research and Reference Program, including
the complete sets of the HIV-1 HXB2 gag
peptides (Cat#5107 and Cat#3992), HIV-1 MN env
peptides (Cat#6451), HIV-1 HXB2R pol peptides
(Cat#4358), HIV-1 clade B nef peptides (Cat#5189),
HIV-1 consensus B vif peptides (Cat#6445), HIV-1
consensus B rev peptides (Cat#6445), HIV-1 BRV nef
peptides (Cat#6441) and HIV-1 consensus vpu
peptides (Cat#6444). Each peptide was dissolved in
DMSO at a concentration of 10mg/ml, and then
diluted in RPMI medium at 10mg/ml prior to use.
Viruses
HIV-1JR-CSF [16] and HIV-1NL4-3 [2] viral stocks were
each produced in the 293T cells by transfection with
A. Yoshida et al. 236the appropriate HIV-1 infectious plasmid DNA
utilizing the calcium phosphate method [33]. HIV-
1IIIB was harvested from Molt-4/IIIB cell cultures.
The 50% tissue culture infectious dose (TCID50) was
determined by an endpoint infectious assay using
PBMC stimulated with anti-CD3/anti-CD28-mAb
conjugated DynaBeads (Dynal, Oslo, Norway).
HIV-1 preparations were inactivated with Aldrithiol-
2 (AT-2), as originally described by Rossio et al. [29].
Generation of HIV-1 pulsed mature DC’s from monocytes
Fresh PBMC at 5 £ 10
6 cells/ml in RPMI medium
were dispensed into individual wells of 12-well plates
(1ml/well), which had been precoated with auto-
logous plasma for 30min at 378C. The PBMC
cultures were allowed to incubate at 378C for 1h.
The non-adherent cells were removed by gentle
washing with serum-free RPMI 1640 medium and
the remaining adherent cells were cultured in Iscove’s
medium (2ml/well) containing human GM-CSF
(500ng/ml) and IL-4 (200ng/ml) for 5 days. The
resulting immature DC cultures were depleted of
contaminating lymphocytes by using the monocyte-
negative isolation kit (Dynal, Oslo, Norway), and the
enriched population of DC’s were further cultured at
2 £ 10
6/ml in human IFN-b (1000U/ml; Toray,
Tokyo, Japan) in the presence of AT-2 inactivated
whole HIV-1 (containing 50ng/ml p24) for 2 days to
obtain mature DC pulsed with HIV-1, as described
previously in ref. [39].
Transplantation and immunization
HIV-1-pulsed mature DC (5 £ 10
5 cells) mixed with
autologous fresh PBMC (3 £ 10
6 cells), or those
depletes of CD8
þ T cells, or CD4
þ T cells by a
magnetic isolation method (Dynal, Oslo, Norway) in a
ﬁnal volume of 100ml in RPMI medium were injected
into the spleen of SCID mice. Five days later, the same
number of DC pulsed with the same dose of HIV-1
antigen were inoculated into the peritoneal cavity. Five
days later, the mice were sacriﬁced and human
lymphocytes were recovered from the spleen and the
peritoneal cavity by lavage.
In vitro re-stimulation of CD4
1 T cells
The recovered human lymphocytes from the HIV-DC
immune mice were depleted of human CD8
þ cells by
the magnetic beads-negative selection method
(Dynal). These enriched population of human
CD4
þ T cells (2 £ 10
6 cells) were co-cultured with
freshly obtained 2 £ 10
5 autologous mitomycin-C
treated adherent PBMC as antigen presenting cells
(APC), in the presence of AT-2 inactivated HIV-1
containing 50ng p24 in a volume of 1ml RPMI 1640
medium supplemented with 20U/ml human IL-2 in
individual wells of a 24-well plate (BD Pharmingen,
San Diego, CA) at 378C. Two days later, these CD4
þ
T cells were assayed for HIV-1 peptide speciﬁc
r e s p o n s e sa sf o l l o w s .A ni n i t i a ls c r e e n i n gw a s
performed utilizing pools of 10 sequential overlapping
peptides and once a pool of peptides was shown to
lead to the synthesis of the HIV-1 suppression factor,
a second screening was performed to identify the
individual peptide. Thus, enriched population of
2 £ 10
4 autologous APC were ﬁrst dispensed in a
volume of 50ml into individual wells of a 96-well
microtiter plate and triplicate wells incubated with
50ml of media containing the various individual pools
of 10 HIV-1 peptides for the primary screen (each at
10mg/ml) or an individual HIV-1 peptide for the
secondary screen (10mg/m) for 1h at 378C. A total of
2 £ 10
5 HIV-1 primed and in vitro re-stimulated
CD4
þ T cells were then added to these cultures in a
volume of 100ml of media and the co-cultures
i n c u b a t e da t3 7 8Ci na5 %C O 2 humidiﬁed
atmosphere. Two days later, the culture supernatants
were harvested and aliquots assayed for HIV-1
inhibition activity and levels of IFN-g.
HIV-1 inhibition and IFN-g assays
As previously reported [39], PBMC were activated
with anti-CD3/28 antibody-coated magnetic beads
(Dynal) at cell to bead ratio of 1:1 in 20U/ml IL-2
containing RPMI medium in vitro for 3 days. These
activated PBMC’s (5 £ 10
5 cells/well) were pre-
incubated at 378C for 1h with either various dilution
of serum from the HIV-DC immune mice or culture
supernatants obtained from the CD4
þ T cells that
were stimulated with various HIV-1 peptides as
described above. Five hundred TCID50 of HIV-1JR-
CSF or HIV-1 NL4-3 was then added to these cultures
for an additional 4h. The microtiter plate was
centrifuged and the supernatant ﬂuid removed. The
procedure repeated three times and the cultures then
were incubated in 0.2ml of 20U/ml IL-2-containing
RPMI medium for 5 days. The levels of HIV-1 p24
produced in the culture supernatants were determined
by a commercial ELISA kit (Zepto Metrix, Buffalo,
NY). Levels of human IFN-g in the stimulated culture
supernatants were assayed utilizing a commercial
ELISA kit (R&D Systems Inc., Minneapolis, MN).
HLA typing
Donor PBMC were HLA typed by a DNA typing
method.
Results
In order to identify the lineage of cells that was the
major producer of the R5 HIV-1 suppression factor in
vivo, SCID mice were engrafted with unfractionated
DC-based HIV-1 vaccination 237PBMC or PBMC depleted of either CD4
þ or CD8
þ
cells, together with HIV-DC. Various dilutions of the
immune sera from these mice were then examined for
the R5 HIV-1 suppression activity in vitro. As seen in
Figure 1, as little as 5% of the sera from the mice
engrafted with either unfractionated PBMC or CD8-
depleted PBMC signiﬁcantly (p , 0.05) inhibited R5
HIV-1 infection. In contrast, up to 20% of the sera
from the CD4-depleted PBMC-engrafted mice did
not show any detectable R5 HIV-1 suppressive
activity. Similar assays conducted using X4 HIV-1
failed to show any inhibition denoting that the
inhibition was selective for R5 HIV-1 (data not
shown). In these engrafted mice, the levels of human
CD4
þ and CD8
þ T cells existed at similar levels as in
the mice engrafted with unfractionated PBMC (data
not shown). These data indicate that CD8
þ T cells are
not required for the production of the R5 HIV-1
suppression factor in vivo, and that the HIV-immune
human CD4
þT cell population is the major source for
the R5 HIV-1 suppression factor in vivo.
In efforts to map the epitopes of HIV-1 antigens that
lead to the activation of CD4
þ T cells and the
subsequent release of the HIV-1 suppression factor, a
large panel of 15–20 mer peptides spanning a wide
range of HIV-1 proteins were screened using a
re-stimulation assay as described in the methods
section. In order to enrich for HIV-1 antigen-
responding CD4
þ T cells in vitro, CD8
þ T cell-
depleted lymphocytes obtained from three groups of
HIV-DC immune hu-PBL-SCID mice, which had
been engrafted with PBMC’s from different individ-
uals, were ﬁrst stimulated with inactivated whole HIV-
1 in the presence of autologous APC in vitro. These
HIV-1-primed enriched CD4
þ T cells were then
re-stimulated by co-culture in the presence of a pool of
10 HIV-1 peptides with fresh APC for primary
screening. After 2 days, culture supernatants were
harvested and examined for the R5 HIV-1 suppression
factor at a ﬁnal dilution of 50%. Supernatant ﬂuids
giving values of .50% reduction compared to
controls (incubated with media alone) in p24 antigen
synthesized in the R5 HIV-1 infected cells were
considered positive and a secondary screen performed
to identify the individual HIV peptide inducing such
HIV-1 suppression factor activity. In order to make
sure that the R5 HIV-1 suppression was not mediated
by CCR5-binding b-chemokines, the culture super-
natants to be tested were individually pre-absorbed by
incubation with Heparin–Sepharose followed by
incubation with a pool of blocking mAbs against
human RANTES, MIP-1a and MIP-1b each a
concentration of 10mg / m l .F i g u r e2 a – cs h o w s
representative data from a number of independent
experiments conducted on cells from the three donors,
respectively. These data suggest that the ability of
HIV-1 peptides to induce the HIV-1 suppressor factor
resides in multiple HIV-1 peptides from a number of
HIV-1 proteins. As expected, there were variations
noted in the HIV-1 proteins and peptides that induce
the HIV-1 suppression factor in the three individual
donors. The peptides recognized by donor 1 CD4
þ T
cells consisted of peptides from HIV-1 pol, gag and
env antigens, while those recognized by donor 2 were
of gag, env, vif and rev antigens, and those recognized
by donor 3 were of gag, env, vif and rev antigens. None
of the supernatant ﬂuids examined showed detectable
X4 HIV-1 suppression activity in the assay employed
(data not shown). There was speciﬁcity in the assay
since the R5 HIV-1 suppression factor was not
detected either in the culture supernatants from
APC cultured with or without HIV-1 peptides alone or
supernatant ﬂuids from immune CD4
þ T cells
cultured in the absence of APC or peptides (data not
shown). The individual variations in the response to
peptides may be due to HLA restriction of responding
antigenic peptides, as the three donors were of
different HLA class II type (Table I). It is interesting
to note that the production of the R5 HIV-1
suppression factor by the bulk CD4
þ T cells was
Figure 1. Requirement of human CD4
þ T cells, but not CD8
þ T cells, to generate the R5 HIV-1 suppression factor in the DC-HIV-immune
hu-PBL-SCID mice. Together with HIV-DC, PBMC or those depleted of CD8
þ or CD4
þ cells were engrafted into the spleen of four SCID
mice per group. After 5 days, mice were boosted with HIV-DC. After 5 days, serum samples from each group were pooled and tested for the
R5 HIV-1 suppression activityon activated PBMC.Bars showthe meansof HIV-1 p24values in the PBMCculturesupernatants on day5 post
infection. HIV-1 proliferation in medium control was 7.7ng/ml.
A. Yoshida et al. 238Figure 2. Recognition of various HIV-1 peptides by HIV-1-immune human CD4
þ T cells from three different donors generated in the HIV-
DC-immunehu-PBL-SCID mice.HIV-DC immune CD4
þ T cells (2 £ 10
5 cells) were stimulated with variouspeptides at a concentrationof
10mg/ml in the presence of 2 £ 10
4 APC in a volume of 200ml in individual wells of a 96-well plate. After 2 days, the culture supernatants
were harvested and their activity of R5 HIV-1 inhibition and the levels of human IFN-g were determined as described in the materials and
methods. Percent inhibition of HIV-1 production was calculated using values obtained from HIV-1 infected PBMC that were pre-treated with
the medium alone. Representative data from three independent experiments for donor 1 (a), donor 2 (b), and donor 3 (c) were shown.
DC-based HIV-1 vaccination 239accompanied by the production of human IFN-g but
not in all the cases.
Discussion
Our laboratory has previously documented the
synthesis of a soluble factor by CD4
þ T cells isolated
from SCID mice previously engrafted with a mixture
of human PBMC’s and HIV-1-pulsed autologous
DC’s which suppressed infection of R5 HIV-1 in vitro
[39]. In the present study we have identiﬁed the
CD4
þT cell lineage as a requirement for the synthesis
of this factor in vivo. In addition, we have attempted
to identify the HIV-1 epitopes that are recognized by
CD4
þ T cells that lead to the synthesis of this factor.
There are a number of issues that need to be
addressed in light of these ﬁndings. Thus, ﬁrst of all,
we submit that the anti-viral factor is distinct from
the other anti-viral factors that have been previously
identiﬁed. The fact that the suppressor activity was
not neutralized by the addition of antibodies against
the chemokines RANTES, MIP-1a and MIP-1b
suggest that such suppression is not likely due to the
synthesis of these chemokines which are known
inhibitors of viral infection [7,36]. The factor
described herein is also distinct from the cellular
anti-viral factor (CAF) identiﬁed by the laboratory of
Dr Jay Levy [19] since it is synthesized by CD4
þ T
cells but not CD8
þ T cells and whereas Dr Levy’s
CAF is effective against all HIV-1, HIV-2 and select
retroviruses. The factor reported herein appears to be
speciﬁc for R5 but not X4 tropic HIV-1. In addition,
it is not likely to be either lymphotactin [35],
a-defensins [40], the heparin binding protein termed
anti-thrombin III [10], the natural killer enhancing
factors A and B [11], and some additional factors
(reviewed by Levy et al. [5]) since all of these have
been shown to be synthesized primarily by CD8
þ but
not CD4
þ T cells. There has been an anti-viral factor
that is synthesized following the interaction of CD4
þ
T cells with APC’s [6]. However, this factor is
functionally distinct from our factor because the
factor inhibits HIV-1 production at post-integration
stage, and our factor inhibits R5 HIV-1 infection
prior to integration [39]. It is clear though that there
are a plethora of such anti-viral factors that have been
and continue to be described. The biologic reasons
for such a multitude of anti-viral factors is difﬁcult to
imagine except to state that these are likely due to
redundancies that nature has bestowed on the
vertebrate species to protest itself from such viral
infections.
The second issue concerns the multiple epitopes of
HIV-1 that induce the generation of this factor by
CD4
þ T cells. These epitopes interestingly were not
restricted to a single HIV-1 protein and included both
viral structural and accessory proteins. The obvious
individual variations in responding antigenic peptides
suggests that this maybe due to HLA-restriction of
peptide recognition by the immune CD4
þ T cells,
although additional studies are necessary to conﬁrm
this issue. Furthermore, the present study suggests
that the CD4 factor-producing HIV-1-immune CD4
þ
T cells are heterogeneous Th clones. Since the
peptides tested in this study were overlapping 15–20
mers, an additional study is required to more precisely
deﬁne the speciﬁc HIV-1 epitope that has speciﬁcity
for the CD4
þ T cells. It is also unclear whether the
suppressor factor synthesized by CD4
þ T cells in
response to distinct HIV peptides is identical or
distinct. Biochemical identiﬁcation of the factor(s) is
needed to address this issue and such studies are in
progress.
The next issue concerns the synthesis of IFN-g by
some but not all the CD4
þT cell in the assays reported
herein. Since the cultures performed consisted of a
mixture of CD4
þ T cells, it is not clear whether the
synthesis of the anti-viral factor and IFN-g was the
result of a single clonal population of multiple clones
of CD4
þ T cells. Clonal analysis needs to be
performed to address this issue.
It is important to note that the HIV-1 gag p17
antigen peptide (LERFAVNPGLLETSE) recognized
by the HIV-DC immune CD4
þ T cells from two out
of the three donors shares amino acid sequence with
another gag p17 peptide (ERFAVNPGLLETSEGCR)
that is widely recognized by IFN-g-producible CD4
þ
T cells from at least 25% HIV-1-infected individuals
[14]. These results strongly support the use of DC-
based vaccination of hu-PBL-SCID mice with whole
inactivated HIV-1 virion to stimulate and expand
HIV-1-speciﬁc CD4
þ T cells in efforts to study the
effectiveness of these cells for anti-viral control. More
importantly, it should be noted that the CD4 factor
producing CD4
þ T cells generated in the hu-PBL-
SCID mice recognize multiple HIV-1 proteins similar
the studies that have reported for HIV-1-speciﬁc IFN-
g producing CD4
þ T cells in HIV-1 infected
individuals [39]. Although, the existence and clinical
role of the CD4 factor in HIV-1-infected individuals
remains unknown, the data reported herein suggest
that HIV-1 vaccines containing multiple HIV-1
epitopes or proteins, rather than those with single
HIV-1 protein or epitope, will be likely to be more
effectivein expanding a large number of multiple HIV-
1-reactive CD4
þ T cells that are capable of producing
the CD4 factor and other helper and HIV-1-
suppresing cytokines.
Table I. HLA class II typing.
DR DQ
Donar 1 15/– 6/–
Donar 2 4/14 4/7
Donar 3 4/13 6/8
A. Yoshida et al. 240As far as we know up to present, there have been no
reports on cytokines that are identical to the CD4 anti-
viral factor described herein. Attempts to identify the
biochemical nature of this novel anti-viral factor have
been hampered by both our inability to prepare
sufﬁciently large quantities that are required for both
biochemical identiﬁcation and detailed characteriz-
ation of this molecule coupled with the labile nature of
the molecule. Fortunately, in our recent attempts, we
have succeeded in immortalizing CD4 factor-produ-
cing CD4
þ T cells by HTLV-I-mediated transform-
ation (Yoshida et al. unpublished). These cells will be
helpful for the identiﬁcation of not only the factor
itself, but also its putative receptor.
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